Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course radiotherapy followed by tislelizumab plus capecitabine as neoadjuvant therapy for locally advanced rectal cancer
ChiCTR2400088935Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and capecitabine in rectal adenocarcinoma, sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: Pathological complete response rate (pCR). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
tislelizumabcapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400088935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088935.